Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489227 · ClinicalTrials.gov registry record · Phase 3
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
NCT02489227: Completed Phase 3 study, sponsored by Coherus Oncology.
NCT02489227 is a Phase 3 study that has completed, run by Coherus Oncology. The registered enrollment target is 545 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02489227, a Phase 3 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
Study Summary
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
Primary Outcome
The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.
Interventions
- DRUG Adalimumab
- DRUG CHS-1420
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
What the finished NCT02489227 record still lists
NCT02489227 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT02489227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02489227 about?
NCT02489227 is a clinical study titled "Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis". This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
What is the current status of trial NCT02489227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2015-08. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02489227?
The interventions under investigation include: Adalimumab (DRUG), CHS-1420 (DRUG).
Who is sponsoring clinical trial NCT02489227?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02489227's enrollment target sits among peer trials
545 689th of 2000 higher than 1,310 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia